March 14, 2022
Life Sciences
  • Sanofi SA’s experimental breast cancer treatment failed in a clinical trial, marking a setback for the drugmaker, which had prioritized the medicine and called it “potentially transformative.” In the phase two study, patients with advanced disease who got the drug didn’t live longer without their illness progressing than those who received endocrine treatment, though Sanofi said it will continue with other tests. (Article here)